Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Quarterly results
|
|
Insys Therapeutics, Inc. (INSY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/10/2019 |
GN
| INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities |
| 05/10/2019 |
GN
| INSYS Therapeutics Reports First Quarter 2019 Results |
| 03/25/2019 |
GN
| INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting |
| 03/07/2019 |
GN
| INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results |
| 03/06/2019 |
GN
| INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7 |
| 02/25/2019 |
GN
| INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting |
| 01/09/2019 |
GN
| INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis |
| 01/03/2019 |
GN
| INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference |
| 12/18/2018 |
GN
| INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone |
| 12/17/2018 |
GN
| INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology |
| 12/04/2018 |
GN
| INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy |
| 11/05/2018 |
GN
| INSYS Therapeutics Reports Third Quarter 2018 Results |
| 11/01/2018 |
GN
| INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose |
| 10/22/2018 |
GN
| INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5 |
| 10/12/2018 |
GN
| INSYS Therapeutics and UC San Diego's Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies |
| 10/10/2018 |
GN
| INSYS Therapeutics Names New General Counsel |
| 10/01/2018 |
GN
| INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East |
| 09/24/2018 |
GN
| INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated Inhaler |
| 09/14/2018 |
GN
| INSYS Therapeutics to Present at Janney Healthcare Conference |
| 09/04/2018 |
GN
| INSYS Therapeutics and UC San Diego's Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis |
| 08/30/2018 |
GN
| FDA Grants INSYS Therapeutics ‘Fast Track' Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis |
| 08/15/2018 |
GN
| Analysis: Positioning to Benefit within Northeast, Hurco Companies, PGT, Bassett Furniture Industries, Insys Therapeutics, and Achaogen — Research Highlights Growth, Revenue, and Consolidated Results |
| 08/08/2018 |
GN
| INSYS Therapeutics Reports Second Quarter 2018 Results |
| 08/08/2018 |
GN
| INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation |
| 07/27/2018 |
GN
| INSYS Therapeutics Receives Complete Response Letter from FDA for Buprenorphine NDA |
| 06/18/2018 |
GN
| INSYS Therapeutics Provides an Update on Its Ongoing Transformation |
| 06/04/2018 |
GN
| INSYS Therapeutics to Present at Jefferies Global Healthcare Conference |
| 05/22/2018 |
GN
| INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray |
| 05/02/2018 |
GN
| New Research: Key Drivers of Growth for SecureWorks, Ingles Markets, Insys Therapeutics, Energous, XO Group, and Forward Air — Factors of Influence, Major Initiatives and Sustained Production |
| 04/27/2018 |
GN
| INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome |
| 04/25/2018 |
GN
| INSYS Therapeutics to Report First Quarter 2018 Results on May 8 |
| 04/18/2018 |
GN
| INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device |
| 04/02/2018 |
GN
| INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors |
| 03/19/2018 |
GN
| INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline |
|
|
|